Inogen (INGN) Competitors $8.12 +0.24 (+3.05%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$8.11 -0.01 (-0.12%) As of 09/4/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INGN vs. TNDM, BBNX, SIBN, AXGN, BVS, AVNS, ZIMV, KIDS, TMCI, and SMLRShould you be buying Inogen stock or one of its competitors? The main competitors of Inogen include Tandem Diabetes Care (TNDM), Beta Bionics (BBNX), SiBone (SIBN), AxoGen (AXGN), Bioventus (BVS), Avanos Medical (AVNS), ZimVie (ZIMV), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), and Semler Scientific (SMLR). These companies are all part of the "medical equipment" industry. Inogen vs. Its Competitors Tandem Diabetes Care Beta Bionics SiBone AxoGen Bioventus Avanos Medical ZimVie OrthoPediatrics Treace Medical Concepts Semler Scientific Tandem Diabetes Care (NASDAQ:TNDM) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends. Does the media prefer TNDM or INGN? In the previous week, Tandem Diabetes Care had 2 more articles in the media than Inogen. MarketBeat recorded 6 mentions for Tandem Diabetes Care and 4 mentions for Inogen. Tandem Diabetes Care's average media sentiment score of 1.66 beat Inogen's score of 0.89 indicating that Tandem Diabetes Care is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tandem Diabetes Care 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Inogen 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TNDM or INGN more profitable? Inogen has a net margin of -7.58% compared to Tandem Diabetes Care's net margin of -20.51%. Inogen's return on equity of -13.77% beat Tandem Diabetes Care's return on equity.Company Net Margins Return on Equity Return on Assets Tandem Diabetes Care-20.51% -65.40% -13.87% Inogen -7.58%-13.77%-8.52% Do insiders and institutionals believe in TNDM or INGN? 89.9% of Inogen shares are owned by institutional investors. 1.9% of Tandem Diabetes Care shares are owned by insiders. Comparatively, 1.5% of Inogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has higher valuation & earnings, TNDM or INGN? Inogen has lower revenue, but higher earnings than Tandem Diabetes Care. Inogen is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTandem Diabetes Care$940.20M0.89-$96.03M-$3.09-4.01Inogen$335.70M0.65-$35.89M-$1.06-7.66 Which has more risk and volatility, TNDM or INGN? Tandem Diabetes Care has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Do analysts recommend TNDM or INGN? Tandem Diabetes Care presently has a consensus target price of $22.47, indicating a potential upside of 81.33%. Inogen has a consensus target price of $11.00, indicating a potential upside of 35.47%. Given Tandem Diabetes Care's higher possible upside, equities research analysts plainly believe Tandem Diabetes Care is more favorable than Inogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tandem Diabetes Care 0 Sell rating(s) 11 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.27Inogen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryTandem Diabetes Care and Inogen tied by winning 8 of the 16 factors compared between the two stocks. Get Inogen News Delivered to You Automatically Sign up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INGN vs. The Competition Export to ExcelMetricInogenMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$213.08M$6.90B$5.76B$9.85BDividend YieldN/A1.22%6.67%4.51%P/E Ratio-7.6626.0675.9926.43Price / Sales0.6570.07546.94119.09Price / CashN/A21.6037.0558.92Price / Book1.114.9010.916.06Net Income-$35.89M$178.27M$3.29B$266.28M7 Day Performance1.63%-0.86%0.18%-0.32%1 Month Performance28.28%2.52%6.26%3.44%1 Year Performance-30.60%10.03%51.54%23.11% Inogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INGNInogen4.0282 of 5 stars$8.12+3.0%$11.00+35.5%-29.9%$213.08M$335.70M-7.661,030Positive NewsTNDMTandem Diabetes Care4.6628 of 5 stars$12.11+1.5%$22.47+85.5%-69.9%$818.27M$940.20M-3.922,650Positive NewsShort Interest ↓BBNXBeta BionicsN/A$17.45+2.3%$22.56+29.3%N/A$758.55M$65.12M0.00294SIBNSiBone4.1559 of 5 stars$16.05-2.1%$23.67+47.5%+0.6%$692.41M$185.26M-28.66350AXGNAxoGen3.2252 of 5 stars$14.79-9.0%$26.00+75.8%+17.9%$680.53M$203.27M-147.89450Short Interest ↓Gap DownHigh Trading VolumeBVSBioventusN/A$7.44-2.6%N/AN/A$615.13M$564.14M14.161,200AVNSAvanos Medical2.6607 of 5 stars$11.58-1.2%N/A-47.0%$537.10M$692.50M-1.152,227Positive NewsZIMVZimVie0.7315 of 5 stars$18.96+0.1%$17.75-6.4%+12.2%$534.67M$449.75M-27.091,770News CoverageKIDSOrthoPediatrics4.4269 of 5 stars$20.29+0.4%$34.14+68.3%-32.5%$508.75M$220.73M-11.34200News CoveragePositive NewsTMCITreace Medical Concepts2.5721 of 5 stars$7.47-3.0%$9.83+31.6%+25.8%$471.88M$209.36M-9.46250Positive NewsAnalyst ForecastSMLRSemler Scientific3.4546 of 5 stars$30.02-4.5%$81.75+172.3%+16.7%$444.60M$56.29M12.35120 Related Companies and Tools Related Companies Tandem Diabetes Care Alternatives Beta Bionics Alternatives SiBone Alternatives AxoGen Alternatives Bioventus Alternatives Avanos Medical Alternatives ZimVie Alternatives OrthoPediatrics Alternatives Treace Medical Concepts Alternatives Semler Scientific Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INGN) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inogen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Inogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INGN Stock Alerts